ACBI1 is a potent and cooperative SMARCA2, SMARCA4 and PBRM1 degrader with DC50s of 6, 11 and 32 nM, respectively. ACBI1 is a PROTAC degrader. ACBI1 shows anti-proliferative activity and can induce apoptosis. It induced anti-proliferative effects and cell death caused by SMARCA2 depletion in SMARCA4 mutant cancer cells and acute myeloid leukemia cells dependent on SMARCA4 ATPase activity[1].
[1] William Farnaby. “BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design.” Nature chemical biology 15 7 (2019): 672–680.
[2] M. Koegl. “Abstract 3849: Structure-based PROTAC design demonstrates BAF complex ATPase vulnerabilities in cancer.” Experimental and Molecular Therapeutics 36 1 (2019).
